Company intelligence / Profile preview

Testing Done Simple

Dover, Delaware, United Stateszoominfo.com ↗

Ownership: Private
Development stage: Other

Overview

Testing Done Simple has developed and commercialized a lateral flow immunoassay for the detection of SARS-CoV-2 nucleoprotein. The product is intended for rapid COVID-19 diagnosis and is designed to be easy to use in point-of-care or at-home settings. No additional clinical pipeline information is available from public sources.

Therapeutic areas: Infectious Diseases
Modalities: DeviceDiagnostic test
Industry: Protein Biomarker Diagnostics

Beyond the preview

Go deeper on Testing Done Simple.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Testing Done Simple.

Explore the full profile